Savara Inc. $SVRA Shares Sold by Frazier Life Sciences Management L.P.

Frazier Life Sciences Management L.P. lessened its stake in Savara Inc. (NASDAQ:SVRA) by 14.0% in the 4th quarter, Holdings Channel reports. The firm owned 9,862,301 shares of the company’s stock after selling 1,600,000 shares during the period. Savara comprises about 1.6% of Frazier Life Sciences Management L.P.’s portfolio, making the stock its 18th largest holding. Frazier Life Sciences Management L.P.’s holdings in Savara were worth $59,470,000 as of its most recent SEC filing.

A number of other large investors have also modified their holdings of SVRA. Prudential Financial Inc. purchased a new stake in shares of Savara during the second quarter worth $30,000. BNP Paribas Financial Markets increased its position in shares of Savara by 52.3% during the second quarter. BNP Paribas Financial Markets now owns 13,473 shares of the company’s stock worth $31,000 after acquiring an additional 4,626 shares during the period. Brevan Howard Capital Management LP purchased a new stake in shares of Savara during the second quarter worth $33,000. Russell Investments Group Ltd. increased its position in shares of Savara by 930.5% during the third quarter. Russell Investments Group Ltd. now owns 10,480 shares of the company’s stock worth $37,000 after acquiring an additional 9,463 shares during the period. Finally, CIBC Bancorp USA Inc. purchased a new stake in shares of Savara during the third quarter worth $44,000. Hedge funds and other institutional investors own 87.93% of the company’s stock.

Savara Stock Performance

Shares of SVRA stock opened at $5.26 on Friday. The company has a current ratio of 13.47, a quick ratio of 13.47 and a debt-to-equity ratio of 0.17. The firm has a fifty day moving average price of $5.29 and a 200 day moving average price of $5.60. The company has a market cap of $1.08 billion, a P/E ratio of -9.39 and a beta of 0.26. Savara Inc. has a 12 month low of $1.98 and a 12 month high of $7.01.

Savara (NASDAQ:SVRA) last issued its earnings results on Tuesday, May 12th. The company reported ($0.15) EPS for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.01). Sell-side analysts predict that Savara Inc. will post -0.57 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research firms have recently weighed in on SVRA. Oppenheimer began coverage on Savara in a research report on Friday, April 24th. They set an “outperform” rating and a $11.00 price objective on the stock. HC Wainwright reaffirmed a “buy” rating on shares of Savara in a research report on Monday, March 16th. Wall Street Zen raised Savara from a “sell” rating to a “hold” rating in a research report on Saturday. William Blair set a $10.00 price objective on Savara in a research report on Monday, March 16th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Savara in a research report on Tuesday, April 21st. One equities research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Savara has a consensus rating of “Moderate Buy” and a consensus target price of $10.14.

Savara Profile

Savara Inc (NASDAQ:SVRA) is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for rare respiratory diseases. The company specializes in in-licensing, advancing and potentially bringing to market novel treatments that address severe pulmonary conditions with high unmet medical need.

The company’s lead candidate, Molgradex (recombinant human granulocyte-macrophage colony-stimulating factor, or GM-CSF), is under regulatory review for the treatment of autoimmune pulmonary alveolar proteinosis (PAP), a rare lung disease characterized by the accumulation of surfactant.